Herein, the strategy for directing BTZ to NSCLC cells hinges on the specific interaction between the cell surface receptor ACE2 and the SARS-CoV-2 spike receptor-binding domain (RBD) (25). This evidence concerns the gene ACE2 and non-small cell lung carcinoma.